Cost per response analysis of nivolumab versus everolimus in the treatment of patients previously treated with advanced renal cell carcinoma-brazil private health care system perspective

Category Primary study
JournalValue in Health
Year 2017
This article has no abstract
Epistemonikos ID: baa10c68b20ec4b564ad4290aed3af1b686d5d08
First added on: Feb 08, 2025